MEMBER'S AREA
GET IN TOUCH
JOIN US!

ICCBH 2026

Saturday 27 June to Tuesday 30 June 2026

ICCBH 2026, 26-30 June, Montreal Canada

Welcome

Dear Colleagues,

We are pleased to invite you to return with us to the beautiful, city of Montreal, Canada for the 12th International Conference on Children’s Bone Health, to be held from Saturday 27 to Tuesday 30 June 2026.

This conference will bring together scientists, clinicians, trainees, allied health professionals and others from a wide range of disciplines to gain a better understanding of the growing skeleton in relation to childhood health and disease and to discuss the most recent developments in clinical outcomes, novel therapies, and genetic discoveries. The conference scope ranges from basic molecular mechanisms to clinical aspects, from bone pathophysiology to prevention and medical and surgical treatment.

We invite anyone with an interest in bone metabolism and bone mass in children, adolescents and young adults to attend.

The ICCBH conference takes place every two years. The 2024 meeting in Salzburg was attended by over 500 participants from across the globe, making it truly multinational and multidisciplinary – a unique networking opportunity. This is one of our favourite times to gather and share our science, knowledge and friendship with our colleagues.

Our scientific programme is designed to present researchers, physicians, and allied health professionals with the newest research, with sessions including plenary lectures by world-leading experts, symposia, workshops, oral abstract communications, poster sessions and meet the expert sessions.

The conference will offer investigators from around the world an opportunity to meet with each other and with industry representatives. There will be plenty of opportunity for discussion both in and outside the lecture theatre and we actively encourage you to submit your abstracts for oral and poster presentation. Our priority is to maximise the time available for presentation of submitted abstracts.

ICCBH 2026 is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health. Come and participate in a lively interactive meeting with the leaders in the field and become part of this expanding network!

We look forward to seeing you in Montreal in June 2026!

Outi Makitie

Chair

Erik Imel

Co-Chair

About

ICCBH meetings provide an international forum for the presentation and discussion of current basic and clinical science in the field of bone metabolism and bone mass in children, adolescents and young adults.

The International Conference on Children’s Bone Health (ICCBH) was started in 1999 by an international group of independent clinicians and researchers interested in bone metabolism and bone mass in children, adolescents, and young adults. Eleven popular and successful conferences have been organised to date, the last being in Salzburg, Austria in 2024.

Some comments from previous ICCBH attendees

“This conference was amazing, both in terms of speakers and organisation”

“One of the friendliest and best organised conferences I have ever attended”

“I spent four wonderful, inspiring, exciting days”

REGISTER YOUR INTEREST
IN ATTENDING
REGISTER YOUR INTEREST
IN SPONSORSHIP

ICCBH 2026 Programme Organising Committee

Outi Mäkitie, Chair (Helsinki, Finland)

Erik Imel, Co-Chair (Indianapolis, USA)

Alex Ireland (Manchester, UK)

Peter Simm (Melbourne, Australia)

Antonella Forlino (Pavia, Italy)

Cathleen Raggio (New York, USA)

ISCBH HOME

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

© 2023 International Society for Children’s Bone Health

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE